PE20030348A1 - Derivados de imidazolidina y su preparacion - Google Patents

Derivados de imidazolidina y su preparacion

Info

Publication number
PE20030348A1
PE20030348A1 PE2002000672A PE2002000672A PE20030348A1 PE 20030348 A1 PE20030348 A1 PE 20030348A1 PE 2002000672 A PE2002000672 A PE 2002000672A PE 2002000672 A PE2002000672 A PE 2002000672A PE 20030348 A1 PE20030348 A1 PE 20030348A1
Authority
PE
Peru
Prior art keywords
alkyl
phenylene
aryl
cycloalkyl
alkylene
Prior art date
Application number
PE2002000672A
Other languages
English (en)
Inventor
Volkmar Wehner
Stefanie Flohr
Horst Blum
Hans Ulrich Stilz
Hartmut Rutten
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PE20030348A1 publication Critical patent/PE20030348A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • C07D233/74Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A DERIVADOS DE IMIDAZOLIDINA DE FORMULA I DONDE W ES UN RESTO DIVALENTE DE LA SERIE R1-AC(R13), R1-A-C(R13)=C, GRUPO a, DONDE LOS SISTEMAS DE ANILLO PUEDEN CONTENER UNO O DOS HETEROATOMOS EN EL ANILLO SELECCIONADOS DE O, S, N, SATURADOS , MONOINSATURADOS, POLIINSATURADOS Y PUEDEN ESTAR SUSTITUIDOS CON 1-3 SUSTITUYENTE R13 IGUALES O DIFERENTES CON UNO O DOS SUSTITUYENTES OXO Y/O SUSTITUYENTES TIOXO, DONDE L ES C(R13) O N Y DONDE m1 Y m2 SON 0-6 PERO LA SUMA m1+m2 ES UNO DE 1-6; Y ES UN GRUPO CARBONILO, TIOCARBONILO, METILENO: A ES UN ENLACE DIRECTO, UNO DE LOS RESTOS DIVALENTES ALQUILENO(C1-C6), CICLOALQUILENO (C3-C7), FENILENO, FENILEN-ALQUILO(C1-C6) Y FENILEN-ALQUENILO (C2-C6), ENTRE OTROS; B ES ALQUILENO C1-C6, ALQUENILENO (C2-C6)-, FENILENO, FENILEN-ALQUILO (C1-C3), ENTRE OTROS; E ES TETRAZOLILO, (R8O)2P(O), ENTRE OTROS; R ES H, ALQUILO C1-C8, CICLOALQUILO C3-C12, ENTRE OTROS; R1 ES H, ALQUILO C1-C10 CON F, CICLOALQUILO C3-C12, ENTRE OTROS; R2 ES H, ALQUILO C1-C8, ARILO C6-C14, ARIL(C6-C14)-ALQUILO(C1-C8) CON ARILO, CICLOALQUILO (C3-C8), ENTRE OTROS; R3 ES H, ALQUILO C1-C10, ARILO C6C-14, ENTRE OTROS; R4 ES H, ALQUILO C1-C10, CON OH, ENTRE OTROS; R5 ES ARILO C6-C14 CON ARIL(C6-C14)-ALQUILO (C1-C8), ENTRE OTROS; R6 ES EL RESTO DE UN AMINOACIDO; R8 ES H, ALQUILO C1-C10, A RILO C6-C14, ENTRE OTROS; R13 ES H, ALQUILO C1-C6, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS DERIVADOS DE IMIDAZOLIDINA SON UTILES PARA EL TRATAMIENTO DE ARTRITIS
PE2002000672A 2001-08-01 2002-07-26 Derivados de imidazolidina y su preparacion PE20030348A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10137595A DE10137595A1 (de) 2001-08-01 2001-08-01 Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung

Publications (1)

Publication Number Publication Date
PE20030348A1 true PE20030348A1 (es) 2003-05-14

Family

ID=7693930

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000672A PE20030348A1 (es) 2001-08-01 2002-07-26 Derivados de imidazolidina y su preparacion

Country Status (30)

Country Link
US (1) US6962937B2 (es)
EP (1) EP1414444B1 (es)
JP (1) JP4676697B2 (es)
KR (1) KR100910930B1 (es)
CN (1) CN1537000B (es)
AR (1) AR036349A1 (es)
AT (1) ATE391504T1 (es)
AU (1) AU2002328931B2 (es)
BR (1) BR0211535A (es)
CA (1) CA2455966C (es)
CO (1) CO5550452A2 (es)
DE (2) DE10137595A1 (es)
DK (1) DK1414444T3 (es)
ES (1) ES2301673T3 (es)
HK (1) HK1066166A1 (es)
HR (1) HRP20040108A2 (es)
HU (1) HUP0401406A3 (es)
IL (2) IL160093A0 (es)
MX (1) MXPA04000041A (es)
MY (1) MY133467A (es)
NO (1) NO326696B1 (es)
NZ (1) NZ530887A (es)
PE (1) PE20030348A1 (es)
PL (1) PL365396A1 (es)
PT (1) PT1414444E (es)
RS (1) RS6104A (es)
RU (1) RU2318815C2 (es)
TW (1) TWI325863B (es)
WO (1) WO2003011288A1 (es)
ZA (1) ZA200400194B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539744A4 (en) 2002-07-11 2007-06-06 Vicuron Pharm Inc N-HYDROXYAMIDE DERIVATIVES WITH ANTIBACTERIAL EFFECT
EP2093218A1 (en) * 2008-02-22 2009-08-26 Ruggero Fariello Arylalkyl substituted imidazolidinones
AU2009244863A1 (en) * 2008-05-05 2009-11-12 Winthrop University Hospital Method for improving cardiovascular risk profile of COX inhibitors
US20130337470A1 (en) 2010-10-25 2013-12-19 Biogen Idec Ma Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMadCAM LEVELS

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE235866C (es)
DE4009506A1 (de) 1990-03-24 1991-09-26 Hoechst Ag Hydantoinderivate
DE4126277A1 (de) 1991-08-08 1993-02-11 Cassella Ag Hydantoinderivate
WO1993013798A1 (en) 1992-01-13 1993-07-22 Biogen, Inc. Treatment for asthma
AU674302B2 (en) 1992-02-12 1996-12-19 Biogen Idec Ma Inc. Treatment for inflammatory bowel disease
DE4207254A1 (de) 1992-03-07 1993-09-09 Cassella Ag 4-oxo-2-thioxoimidazolidin-derivate
DE4213634A1 (de) 1992-04-24 1993-10-28 Cassella Ag 2,4-Dioxo-imidazolidin-Derivate
DE4224414A1 (de) 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
DE4228717A1 (de) 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
WO1994015958A2 (en) 1993-01-08 1994-07-21 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
AU688751B2 (en) 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
NZ262615A (en) 1993-02-09 1996-02-27 Biogen Inc Treating insulin dependent diabetes (type i) with anti vla4 (very late antigen) antibodies
DE4308034A1 (de) 1993-03-13 1994-09-15 Cassella Ag Neue Heterocyclen, ihre Herstellung und ihre Verwendung
DE4427979A1 (de) 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
CN1211123C (zh) 1994-01-25 2005-07-20 雅典娜神经科学公司 抗白细胞粘附分子vla-4的人源化抗体
AU2958195A (en) 1994-06-29 1996-01-25 Texas Biotechnology Corporation Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
DE19515177A1 (de) 1995-04-28 1996-10-31 Cassella Ag Hydantoinderivate als Zwischenprodukte für pharmazeutische Wirkstoffe
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
ATE212990T1 (de) 1996-03-20 2002-02-15 Hoechst Ag Inhibitoren der knochenresorption und vitronectinrezeptor-antagonisten
AU3738597A (en) 1996-07-25 1998-02-20 Biogen, Inc. Molecular model for vla-4 inhibitors
DE19647381A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647380A1 (de) 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
PL323130A1 (en) 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
WO1998042656A1 (en) 1997-03-21 1998-10-01 Cytel Corporation Novel compounds
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
EP1027328B1 (en) 1997-10-31 2006-08-23 Aventis Pharma Limited Substituted anilides
GB9723789D0 (en) 1997-11-12 1998-01-07 Zeneca Ltd Chemical compounds
DE19751251A1 (de) * 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
WO1999054321A1 (en) 1998-04-21 1999-10-28 Aventis Pharma Limited Substituted diamines and their use as cell adhesion inhibitors
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR20010083081A (ko) 1998-06-30 2001-08-31 실버스타인 아써 에이. 염증성질환, 자가면역질환 및 호흡기질환을 치료하는데유용한 브이엘에이-4-의존성 세포 결합의 비-펩티딜 억제제
WO2000002903A1 (en) 1998-07-10 2000-01-20 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
DE19922462A1 (de) * 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
TWI325863B (en) 2010-06-11
US20030109497A1 (en) 2003-06-12
MY133467A (en) 2007-11-30
PT1414444E (pt) 2008-05-27
KR20040020076A (ko) 2004-03-06
DK1414444T3 (da) 2008-08-04
MXPA04000041A (es) 2004-05-21
CA2455966C (en) 2011-09-20
JP4676697B2 (ja) 2011-04-27
CO5550452A2 (es) 2005-08-31
DE10137595A1 (de) 2003-02-13
RU2318815C2 (ru) 2008-03-10
KR100910930B1 (ko) 2009-08-06
CA2455966A1 (en) 2003-02-13
EP1414444A1 (en) 2004-05-06
JP2005504033A (ja) 2005-02-10
NO20040426L (no) 2004-03-26
WO2003011288A1 (en) 2003-02-13
ES2301673T3 (es) 2008-07-01
ZA200400194B (en) 2005-03-14
CN1537000A (zh) 2004-10-13
AR036349A1 (es) 2004-09-01
HUP0401406A2 (hu) 2004-10-28
IL160093A0 (en) 2004-06-20
PL365396A1 (en) 2005-01-10
NZ530887A (en) 2005-09-30
HK1066166A1 (en) 2005-03-18
AU2002328931B2 (en) 2008-04-24
RU2004105966A (ru) 2005-06-27
DE60226032T2 (de) 2009-05-20
DE60226032D1 (de) 2008-05-21
BR0211535A (pt) 2004-07-13
US6962937B2 (en) 2005-11-08
ATE391504T1 (de) 2008-04-15
CN1537000B (zh) 2010-05-12
HRP20040108A2 (en) 2004-06-30
IL160093A (en) 2009-05-04
NO326696B1 (no) 2009-02-02
RS6104A (en) 2006-10-27
HUP0401406A3 (en) 2004-11-29
EP1414444B1 (en) 2008-04-09

Similar Documents

Publication Publication Date Title
DE10199068I1 (de) Sublinguale Dosierungsformen enthaltend Apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion
AR040286A1 (es) Proceso para la preparacion de pirimidinas sustituidas
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
AR054881A1 (es) Inhibidores macrociclicos de la replicacion del virus de la hepatitis c, un proceso para su preparacion, una composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento para el tratamiento de la hepatitis c
UY27779A1 (es) Compuestos químicos
PE20060371A1 (es) Derivados de metastina en el tratamiento del cancer
BR9917080A (pt) Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica
ES2118250T3 (es) Combinaciones germicidas de substancias activas.
AR033383A1 (es) Derivados de acridina, procedimiento para prepararlos, el uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
RU2011129764A (ru) Лекарственные средства, связанные с дипептидами
AR024918A1 (es) Derivados de ciclobuteno, su preparacion y sus usos terapeuticos.
DE69229442D1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
ECSP088525A (es) Proceso para la preparación de aminas
IL163625A0 (en) Alkoxy-pyridine derivatives and pharmaceutical compositions containing the same
DE69305492D1 (de) Im intracerebralen bereich verweisende verbindungen und deren anwendung
ES2135769T3 (es) Derivados de isotiourea como inhibidores de no-sintasa.
PE20030348A1 (es) Derivados de imidazolidina y su preparacion
AR035137A1 (es) Composicion farmaceutica para inhibir metastasis o prevenir recurrencia de tumor maligno
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
DE602004008863D1 (de) Zusammensetzung und Verfahren zur Behandlung von Halbleitersubstraten
CY1109762T1 (el) Νεα κρυσταλλικη μορφη toy 8-kyan-1-kykλoπpoπyλ-7-(1s,6s-2,8-διαζαδικυκλο[4.3.0]εννεαν-8-υλ)-6-φθορο-1,4-διυδρο-4-οξο-3-κινολινο-καρβοξυλικου οξεος
ATE273985T1 (de) Ruthenium (ii) verbindungen in der krebsbehandlung
AR021970A1 (es) Inhibidores de proteasas
ATE376422T1 (de) Diclazurilhaltige antiprotozoenmittel

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed